Due to their specific efficacy, safety and resistance profile, new combined antiretroviral therapies could potentially be administered before the results of genotype profiling, allowing for treatment of patients immediately after diagnosis which in turn limits disease transmission. 

We developed a transmission model to determine the possible impact of test & treat with novel cART at the population level in France by modelling the impact of quicker treatment initiation on HIV transmission and reduced rates of lost to follow-up patients.